DualityBio
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, DualityBio sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
DualityBio: 10 sponsored US clinical trials, 9 recruiting.
DualityBio sponsors 10 registered US clinical trials on ClinicalTrials.gov, 9 of them currently recruiting. 1 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Advanced Solid Tumor, with 2 trials.
Top-decile sponsor footprint
DualityBio ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Open and recent trials
10 total, page 1 of 1
A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors
NCT07263594
A Study of DB-1317 in Selected Advanced/Metastatic Solid Tumors
NCT07141706
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
NCT06953089
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants
NCT06625671
First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors
NCT06554795
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
NCT05914116
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741
First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors
NCT05438329
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 1 |
| Phase 3 | 1 |
What is open in the DualityBio pipeline
9 recruiting of 10 indexed (90% open).
Phase mix: 1 late (III/IV) vs 9 early (I/II) (early-phase heavy).
Top condition: Advanced Solid Tumor (2 trials), 7 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
DualityBio: open-pipeline peers nationwide
Peers matched on 10 registered trials and 90% open enrollment, not the therapeutic-area sidebar.
DualityBio sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 trials (± recruiting share)
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Aevi Genomic Medicine, LLC, a Cerecor company · 10 trials · 0% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
Sponsors near 90% open enrollment (± trial volume)
- Ottawa Heart Institute Research Corporation · 90% recruiting · 10 trials
- Efforia · 89% recruiting · 19 trials
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · 93% recruiting · 14 trials
- Johnson & Johnson Enterprise Innovation · 86% recruiting · 7 trials
Related
What to do with this DualityBio page
10 registered trials is a research-attention snapshot, not an endorsement of DualityBio or any single study.
- 9 of DualityBio's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Advanced Solid Tumor is the condition DualityBio studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Advanced Solid Tumor trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
DualityBio pipeline card: 10 registered trials from official public datasets.Report a data error.